
Adelaide A Hebert MD
Pediatric Dermatology
Department of Dermatology, The University of Texas Medical School-Houston
Join to View Full Profile
6500 West Loop SSte 200ABellaire, TX 77401
Phone+1 713-500-8260
Fax+1 713-524-3432
Dr. Hebert is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Medical Branch HospitalsResidency, Dermatology, 1981 - 1984
University of Texas Medical Branch HospitalsInternship, Internal Medicine, 1980 - 1981
Tulane University School of MedicineClass of 1980
Certifications & Licensure
TX State Medical License 1981 - 2027
LA State Medical License 1980 - 2016
IL State Medical License 1984 - 1987
American Board of Dermatology Dermatology
American Board of Dermatology Pediatric Dermatology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
- Join now to see all
Clinical Trials
- Cutivate Lotion HPA Axis Pediatric Study Start of enrollment: 2007 Jul 01
- New Topical Treatment for Continued Pain After Shingles Start of enrollment: 2006 Sep 01
- Novel Topical Treatment of Hand Dermatitis (Eczema) Start of enrollment: 2006 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis.Linda Stein Gold, Matthew J Bruno, G Michael Lewitt, Adelaide A Hebert
The Journal of Dermatological Treatment. 2025-12-01 - Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials.Kim A Papp, James Q Del Rosso, Mark G Lebwohl, Melinda J Gooderham, Adelaide A Hebert
Dermatology and Therapy. 2025-10-24 - 3 citationsSkin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial ...Robert Bissonnette, Linda Stein Gold, Leon Kircik, Eric L Simpson, Lawrence F Eichenfield
Journal of the American Academy of Dermatology. 2025-09-01
Journal Articles
- Glycopyrronium Tosylate in Pediatric Primary Axillary Hyperhidrosis: Post Hoc Analysis of Efficacy and Safety Findings by Age from Two Phase Three Randomized Controlle...Douglass W Forsha, David M Pariser, Adelaide A Hebert, Dee Anna Glaser, William P Werschler, Pediatric Dermatology
- The Cutaneous Manifestations of Tuberous Sclerosis ComplexMary D DarConte, Adelaide A Hebert, American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Efficacy and Safety of Topical Rapamycin in Patients with Facial Angiofibromas Secondary to Tuberous Sclerosis ComplexAdelaide A Hebert, Joshua A Samuels, John M Slopis, JAMA
Lectures
- Late-breaking Research: Clinical TrialsAmerican Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019
- Women's & Pediatric Dermatology Seminar 2013Global Academy for Medical Education (Elsevier), Newport Beach, California - 10/4/2013
- Women's & Pediatric Dermatology Seminar 2013Global Academy for Medical Education (Elsevier), Newport Beach, California - 10/4/2013
Press Mentions
Nonsteroidal Topical OK'd for Atopic DermatitisDecember 17th, 2024
FDA Approves VTAMA® (Tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderDecember 16th, 2024
FDA Approves Tapinarof Cream 1% for Atopic Dermatitis in Adults and ChildrenDecember 16th, 2024- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









